S&P 500
(0.86%) 5 248.49 points
Dow J
(1.22%) 39 760 points
Nasdaq
(0.51%) 16 400 points
Oil
(1.30%) $82.41
Gas
(1.05%) $1.736
Gold
(1.70%) $2 227.90
Silver
(-0.12%) $24.72
Platinum
(0.87%) $917.60
USD/EUR
(0.16%) $0.925
USD/NOK
(0.48%) $10.82
USD/GBP
(-0.03%) $0.791
USD/RUB
(0.39%) $92.80

Realtime updates for Ocular Therapeutix Inc [OCUL]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
85.71%
return 17.05%
SELL
50.00%
return -8.29%
Last Updated28 Mar 2024 @ 09:51

-0.86% $ 9.23

SELL 61570 min ago

@ $6.41

Issued: 14 Feb 2024 @ 14:41


Return: 44.00%


Previous signal: Feb 14 - 13:57


Previous signal: Buy


Return: 2.72 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 09:51):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology...

Stats
Today's Volume 44 760.00
Average Volume 2.08M
Market Cap 1.37B
EPS $0 ( 2024-03-11 )
Next earnings date ( $-0.180 ) 2024-05-13
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -9.05
ATR14 $0.0190 (0.21%)
Insider Trading
Date Person Action Amount type
2024-02-26 Summer Road Llc Buy 930 851 Common Stock, $0.0001 par value per share
2024-02-22 Dugel Pravin Buy 1 282 469 Stock Option (Right to Buy)
2024-02-22 Dugel Pravin Buy 854 979 Common Stock
2024-02-22 Nayak Sanjay Buy 244 550 Stock Option (Right to Buy)
2024-02-22 Nayak Sanjay Buy 80 300 Common Stock
INSIDER POWER
97.63
Last 98 transactions
Buy: 9 847 283 | Sell: 256 052

Volume Correlation

Long: -0.12 (neutral)
Short: -0.46 (neutral)
Signal:(45.63) Neutral

Ocular Therapeutix Inc Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ocular Therapeutix Inc Correlation - Currency/Commodity

The country flag 0.57
( weak )
The country flag 0.01
( neutral )
The country flag 0.00
( neutral )
The country flag 0.12
( neutral )
The country flag -0.60
( weak negative )
The country flag 0.21
( neutral )

Ocular Therapeutix Inc Financials

Annual 2023
Revenue: $58.44M
Gross Profit: $53.16M (90.96 %)
EPS: $-0.940
Q4 2023
Revenue: $14.80M
Gross Profit: $13.42M (90.64 %)
EPS: $-0.350
Q3 2023
Revenue: $14.95M
Gross Profit: $13.57M (90.79 %)
EPS: $-0.00610
Q2 2023
Revenue: $15.19M
Gross Profit: $13.88M (91.41 %)
EPS: $-0.260

Financial Reports:

No articles found.

Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators